Statement from Beth Battaglino, RN-C CEO, HealthyWomen, concerning entry to oral contraception:

The FDA approval of the primary over-the-counter (OTC) progestin-only oral contraception, Opill, is a vital step towards dramatically growing entry to contraception throughout the nation. Reflecting the sturdy physique of scientific evidence, HealthyWomen helps OTC entry to hormonal contraceptives for girls and folks assigned feminine at start and the precise of all people to entry complete sexual and reproductive well being providers to make selections that meet their very own wants.

Although some legislative approaches have elevated entry in some states, necessities comparable to pharmacy disbursement nonetheless stay barriers for a lot of. Given the scientific proof displaying entry to OTC contraception may be achieved safely, the FDA’s approval will assist mitigate obstacles, empowering extra folks to regulate their very own reproductive futures, together with avoiding unplanned being pregnant.

However, Opill have to be inexpensive, a significant component towards making certain that girls, particularly these with out medical health insurance, are in a position to entry this new possibility.

HealthyWomen will proceed to offer management by way of coverage advocacy and client and HCP schooling, and to help analysis associated to modern methods to broaden entry, security and affordability of hormonal contraceptives.

From Your Site Articles

Related Articles Around the Web

Leave a comment

Your email address will not be published. Required fields are marked *